Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80192 |
Name | relapsed/refractory diffuse large B-cell lymphoma |
Definition | A diffuse large B-cell lymphoma characterized by less than 50 percent decrease in lesion size with induction therapy or the appearance of new lesions or the appearance of new lesions after attainment of complete remission. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03340766 | Phase I | Blinatumomab + Pembrolizumab | Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348) | Completed | USA | NLD | FRA | ESP | DEU | AUS | 0 |
NCT03401853 | Phase II | Pembrolizumab + Rituximab | Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03533283 | Phase I | Glofitamab-gxbm + Obinutuzumab Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq + Tocilizumab Atezolizumab + Glofitamab-gxbm + Obinutuzumab + Tocilizumab | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Active, not recruiting | USA | ITA | ISR | GBR | ESP | DNK | BEL | 0 |
NCT03579927 | Phase Ib/II | Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | Withdrawn | USA | 0 |
NCT03642626 | Phase II | Cyclophosphamide + Fludarabine + Tisagenlecleucel axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Active, not recruiting | USA | 0 |
NCT03666988 | Phase I | GSK3368715 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | Terminated | USA | ESP | CAN | AUS | 0 |
NCT03684694 | Phase I | Ibrutinib + Loncastuximab tesirine-lpyl | Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | Terminated | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT03688152 | Phase I | INCB053914 + Parsaclisib | A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma | Completed | USA | 0 |
NCT03736616 | Phase II | Acalabrutinib Carmustine + Cytarabine + Etoposide + Melphalan Acalabrutinib + Carboplatin + Etoposide + Ifosfamide + Rituximab | Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | Unknown status | USA | 0 |
NCT03798314 | Phase I | Nivolumab + Pomalidomide | Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma | Completed | USA | 0 |
NCT04156828 | Phase I | Carboplatin + Copanlisib + Dexamethasone + Gemcitabine + Pegfilgrastim + Rituximab | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | Terminated | USA | 0 |
NCT04220008 | Phase II | Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | Withdrawn | 0 | |
NCT04285268 | Phase II | Bortezomib + Rituximab + Venetoclax | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Withdrawn | USA | 0 |
NCT04416984 | Phase Ib/II | ALLO-501A ALLO-647 + Cyclophosphamide + Fludarabine | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2) (ALPHA-2) | Recruiting | USA | ITA | ESP | CAN | AUS | 0 |
NCT04502394 | Phase Ib/II | Acalabrutinib + KRT-232 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Unknown status | USA | POL | ITA | GBR | FRA | CZE | CHE | BEL | AUS | 2 |
NCT04855253 | Phase Ib/II | E7777 | Study of E7777 Prior to Kymriah for R/R DLBCL | Recruiting | USA | 0 |
NCT04906096 | Phase II | GDC-0084 | Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | Recruiting | USA | 0 |